6L60 Stock Chart & Stats
€5.55
--
Market closed
€5.55
--
Day’s Range― - ―
52-Week Range€4.06 - €9.60
Previous CloseN/A
VolumeN/A
Average Volume (3M)0.00
Market Cap
€246.43M
Enterprise Value€292.82M
Total Cash (Recent Filing)€64.64M
Total Debt (Recent Filing)€43.14M
Price to Earnings (P/E)―
Beta1.79
Next Earnings
Aug 06, 2026EPS Estimate
-0.54Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.16
Shares Outstanding52,202,965
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.10
Price to Book (P/B)3.77
Price to Sales (P/S)6.53
P/FCF Ratio-3.82
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€14.23Price Target Upside156.43% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering6
EPS Forecast (FY)-2.06
Revenue Forecast (FY)€53.65M
Bulls Say, Bears Say
Bulls Say
Revenue And Gross Margin RecoverySustained revenue growth and a material gross margin rebound indicate improving unit economics and product adoption. Higher gross margins (guided 55%–58%) reduce the revenue required to approach profitability and improve long‑term cash conversion if scale persists.
In‑house U.S. Commercial Integration And DTC ScaleOwning U.S. commercial execution and a rapidly scaling DTC channel provide durable control over customer acquisition, pricing and margins. Scaled DTC plus Eon Care insertion capacity reduces access friction and creates a repeatable distribution engine for long‑term growth.
Long‑duration Product Pipeline And IntegrationsA multiyear sensor roadmap and AID integrations create structural differentiation versus competitors. Regulatory progress and ecosystem partnerships expand use cases, support clinician adoption, and can sustain premium positioning and retention over the medium term.
Bears Say
High Cash Burn And Funding DependenceLarge negative operating and free cash flow and guidance for substantial 2026 cash utilization mean the company must continue accessing capital. Reliance on external funding increases dilution and execution risk if capital markets tighten or performance slips versus plan.
Elevated Leverage And Weakened Equity BaseRising leverage and shrinking equity reduce financial flexibility and increase interest and covenant risks. Higher debt levels could constrain the firm's ability to fund commercialization and trials without costly refinancing or additional equity issuance.
Large Operating Expense Run‑rate From CommercializationA materially higher SG&A and operating expense plan to support in‑house commercialization pushes the breakeven horizon outward. If DTC efficiency or clinician uptake underperforms, sustained elevated expenses could prolong losses and pressure cash needs.
Senseonics Holdings News
6L60 FAQ
What was Senseonics Holdings Inc.’s price range in the past 12 months?
Senseonics Holdings Inc. lowest stock price was €4.06 and its highest was €9.60 in the past 12 months.
What is Senseonics Holdings Inc.’s market cap?
Senseonics Holdings Inc.’s market cap is €246.43M.
When is Senseonics Holdings Inc.’s upcoming earnings report date?
Senseonics Holdings Inc.’s upcoming earnings report date is Aug 06, 2026 which is in 24 days.
How were Senseonics Holdings Inc.’s earnings last quarter?
Senseonics Holdings Inc. released its earnings results on May 07, 2026. The company reported -€0.623 earnings per share for the quarter, missing the consensus estimate of -€0.602 by -€0.021.
Is Senseonics Holdings Inc. overvalued?
According to Wall Street analysts Senseonics Holdings Inc.’s price is currently Undervalued.
Does Senseonics Holdings Inc. pay dividends?
Senseonics Holdings Inc. does not currently pay dividends.
What is Senseonics Holdings Inc.’s EPS estimate?
Senseonics Holdings Inc.’s EPS estimate is -0.54.
How many shares outstanding does Senseonics Holdings Inc. have?
Senseonics Holdings Inc. has 52,202,965 shares outstanding.
What happened to Senseonics Holdings Inc.’s price movement after its last earnings report?
Senseonics Holdings Inc. reported an EPS of -€0.623 in its last earnings report, missing expectations of -€0.602. Following the earnings report the stock price went up 2.294%.
Which hedge fund is a major shareholder of Senseonics Holdings Inc.?
Currently, no hedge funds are holding shares in DE:6L60
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Senseonics Holdings Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€14.23 (156.43% Upside)
€14.23 (156.43% Upside)
Blogger Sentiment
Bullish
DE:6L60 Sentiment 70%
Sector Average 69%
Sector Average 69%
Insider Transactions
Bought Shares
Worth €110.2K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Negative
20 days / 200 days
Momentum
-46.20%
12-Months-Change
Fundamentals
Return on Equity
-130.00%
Trailing 12-Months
Asset Growth
17.94%
Trailing 12-Months
Company Description
Senseonics Holdings Inc.
Senseonics Holdings, Inc. operates as a medical technology enterprise, specializing in the development and commercialization of continuous glucose monitoring (CGM) systems. These innovative solutions cater to individuals with diabetes across the United States, Europe, the Middle East, and Africa. The company's core product offerings, Eversense and Eversense XL, are advanced implantable CGM devices. They function by continuously tracking glucose levels through an under-the-skin sensor, a detachable and rechargeable smart transmitter, and an intuitive mobile application. This setup enables real-time diabetes monitoring and management for durations of up to half a year. Senseonics delivers its products and services to healthcare providers and patients alike via an extensive network of distributors and strategic fulfillment partners. Additionally, the firm maintains a collaborative agreement with the University Hospitals Accountable Care Organization. Founded in 1996, Senseonics Holdings, Inc. is headquartered in Germantown, Maryland.
6L60 Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call highlighted strong commercial momentum and validating financial results: Q1 revenue of $11.7M (up 85% YoY), a 58% gross margin, rapid DTC growth (~100% YoY) and successful U.S. commercial integration. Management raised 2026 revenue guidance to $60M–$64M (70%–82% growth) and advanced pipeline milestones (Gemini and Freedom) while adding substantial growth capital ($92M equity + expanded $140M credit facility with a $20M draw). Offsetting these positives are materially higher operating expenses and an expanded net loss driven by in‑house commercialization, significant planned cash burn ($110M–$120M for 2026), increased debt, and remaining execution risk in the European transition and competitive landscape. On balance, the highlights from stronger-than-expected top-line performance, margin expansion and financing to fund growth outweigh the near-term cost and cash challenges, but execution through the rest of 2026 will be key.View all DE:6L60 earnings summaries6L60 Stock 12 Month Forecast
Average Price Target
€14.23
▲(156.43% Upside)
Options Prices
Currently, No data available
---